辉瑞及BioNTech测试注射第三剂新冠疫苗能否应付变种新冠
美国辉瑞药厂(PFE.US)及德国生物科技公司BioNTech(BNTX.US)宣布正新其研发的新冠疫苗进行测试,以检视注射第三剂疫苗对应付变种新冠病毒的效用。测试是以接种者完成接种两剂疫苗6至12个月後,接受第三剂疫苗注射,以检视抗体应对变种新冠病毒的能力。药厂将招募参与第一阶段测试的美国志愿者进行测试。
药厂强调,没有证据显示目前疫苗不能应对变种新冠病毒,测试为预备应对出现疫苗无法预防新变种的情况。BioNTech表示,采用mRNA技术疫苗平台,能使他们数周内研发强化疫苗。他们会采取步骤以确保长期对变种病毒免疫。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.